Clinical Burden of Recurrent Disease in High-Risk Endometrial Cancer.

ABSTRACT:

Introduction

Disease-free survival (DFS) is commonly a primary endpoint in clinical trials of investigational therapies for early stage and/or high-risk endometrial cancer and may be indicative of therapeutic benefit prior to maturity of overall survival (OS) data; however, its role as a predictor of OS in high-risk endometrial cancer is unknown. Therefore, this study estimates the individual-level correlation between DFS and OS and the association between recurrent disease and OS in patients with high-risk endometrial cancer receiving adjuvant chemotherapy.

Methods

Medicare beneficiaries with high-risk endometrial cancer who underwent surgery followed by adjuvant chemotherapy were identified from Surveillance, Epidemiology, and End Results data (2007-2019). OS and DFS from

SUBMITTER: Kponee-Shovein K 

PROVIDER: S-EPMC12647473 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature